Table 1 Examples of cytotoxic and targeted drugs showing promising activity towards hereditary cancers
Hereditary cancer type | Drug |
|---|---|
BRCA1/2-driven cancers (breast, ovarian, prostate, pancreatic, stomach, etc.) | Genotoxic agents: platinum compounds, PARP inhibitors, mitomycin C, pegylated doxorubicin, etc.; high dose chemotherapy |
Hereditary non-polyposis colorectal cancer | Immune checkpoint inhibitors: pembrolizumab |
Familial adenomatous polyposis | Non-steroidal anti-inflammatory drugs (sulindac) and EGFR inhibitors (erlotinib) |
Tumors arising in patients with tuberous sclerosis (giant-cell astrocytomas, angiomyolipomas) | mTOR inhibitors: everolimus |
Tumors associated with the basal-cell nevus syndrome (basal-cell carcinomas, keratocystic odontogenic tumors) | SMO inhibitors (vismodegib), COX2 inhibitors (celecoxib), antifungal drugs with Hedgehog pathway inhibitory activity (itraconazole) |
Hereditary medullary thyroid cancer | RET inhibitors (vandetanib, cabozantinib) |